Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Fowler, N. H., de Vos, S., Schreeder, M. T., Leonard, J. P., Flinn, I. W., Coutre, S., Wagner-Johnston, N. D., Sharman, J., Boccia, R. V., Barrientos, J. C., Boyd, T. E., Holes, L. M., Lannutti, B. J., Johnson, D., Jahn, T. M., Miller, L. L., Godfrey, W. R. AMER SOC HEMATOLOGY. 2012
View details for Web of Science ID 000314049600297